BETHESDA, Md., April 10, 2012 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – would like to remind investors and analysts that the management will host a conference call to provide a business update and answer questions tomorrow, April 11, 2012 beginning at 1:00 p.m. Eastern time. During the call management will review the Company's 2011 financial results, and provide an update on its development progress, including work with SPX-106T.
Last year Spherix undertook an asset-centric growth strategy based on SPX-106T, and is now launching a combination-drug discovery platform based on a dynamic data-driven application simulation (DDDAS) approach. In addition to its own combination drugs, Spherix is looking at Phase 1 and Phase 2 assets to roll-up in this platform. The DDDAS program began at the National Science Foundation and is now being employed to model complex metabolic disease pathways, test potential binary therapies in simulations of various combinations and choose the most effective pair-wise combinations. DDDAS is being deployed in animal and human studies planned by Spherix.
To access the conference call, from the U.S. please dial (866) 322-1352 and from outside the U.S. please dial (706) 643-6246. All listeners should provide the following passcode: 62805777. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website, www.spherix.com.
Following the end of the conference call, a telephone replay will be available through April 17, 2012, and can be accessed by dialing (855) 859-2056 from the U.S. or (404) 537-3406 from outside of the U.S. All listeners should provide the following passcode: 62805777. The webcast will be available for 30 days.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV